Stroke Therapy Academic Industry Roundtable

Stroke Therapy Academic Industry Roundtable
Name	Stroke Therapy Academic Industry Roundtable
Abbreviation	STAIR
Formation	1999
Type	Non-profit consortium
Headquarters	United States
Region served	International
Membership	Academic investigators; pharmaceutical and device companies; regulatory agencies

Stroke Therapy Academic Industry Roundtable

Stroke Therapy Academic Industry Roundtable convenes leaders from National Institutes of Health, Food and Drug Administration, pharmaceutical corporations such as Pfizer and GlaxoSmithKline, academic centers like Massachusetts General Hospital and Johns Hopkins Hospital, and patient advocacy organizations including American Heart Association and American Stroke Association to improve translational pathways in ischemic and hemorrhagic stroke. The consortium arose amid concerns voiced in publications from groups including European Stroke Organisation and World Health Organization about failed neuroprotective trials, seeking alignment among stakeholders such as AstraZeneca, Bayer, Novartis, Imperial College London, and University of California, San Francisco.

History

STAIR was initiated at a time when high-profile failures reported in journals like The Lancet and New England Journal of Medicine prompted a reassessment of preclinical and clinical strategies. Early meetings included representatives from British Heart Foundation, Wellcome Trust, European Medicines Agency, and the National Institute of Neurological Disorders and Stroke, and were influenced by work at institutions such as University of Cambridge and Stanford University. Foundational reports paralleled initiatives by Cooperative Studies Program and echoed reform efforts exemplified by CONSORT and PRISMA guidelines developed by groups including Cochrane Collaboration and The BMJ. Over successive iterations STAIR incorporated perspectives from World Stroke Organization conferences and consultations with regulatory bodies like Health Canada and Medicines and Healthcare products Regulatory Agency.

Organization and Membership

Membership spans senior investigators from Columbia University, Yale University, University of Oxford, and industry representatives from Eli Lilly, Roche, Medtronic, and Stryker. Regulatory participation includes delegations from FDA and European Medicines Agency, while funders such as Bill & Melinda Gates Foundation and Wellcome Trust have engaged as observers. Working groups have featured methodologists affiliated with Johns Hopkins Bloomberg School of Public Health, statisticians from Emory University, and trialists from Mayo Clinic. The platform operates through steering committees, ad hoc panels, and task forces that mirror organizational models used by International Committee of Medical Journal Editors and World Health Organization advisory panels.

Goals and Activities

STAIR's principal goals include harmonizing preclinical stroke models developed at sites like Harvard Medical School and Karolinska Institutet, improving clinical trial design used in multicenter efforts such as those coordinated by StrokeNet, and enhancing translational fidelity between bench research at laboratories including Salk Institute and bedside practice at hospitals such as Cleveland Clinic. Activities encompass consensus statement development, methodological recommendations influenced by CONSORT standards, and workshops held in venues like Royal College of Physicians and National Academy of Sciences. Collaborations extend to device innovators at Boston Scientific and imaging experts from Siemens Healthineers and GE Healthcare to address biomarkers and outcome measures recommended by groups such as International Stroke Trial investigators.

Major Conferences and Publications

STAIR convenings have been hosted alongside meetings of American Heart Association, European Stroke Organisation Conference, and symposiums at Society for Neuroscience gatherings. Signature publications include consensus recommendations published in outlets like Stroke (journal), Neurology (journal), and The Lancet Neurology, often coauthored by authors from University College London, University of Toronto, and University of Melbourne. White papers and methodological papers have influenced trial designs used in landmark studies led by investigators at Duke University and University of Pennsylvania, and have been cited in guidance from European Medicines Agency and FDA briefings.

Impact on Stroke Research and Clinical Practice

STAIR recommendations reshaped preclinical standards used in laboratories at Max Planck Society affiliates and promoted multi-species, multi-center replication prior to clinical translation, a change reflected in grant reviews by National Institutes of Health panels. Clinical trial protocols influenced by STAIR have been implemented in randomized controlled trials run by Vanderbilt University Medical Center and University of Chicago and have informed stroke unit practices in hospitals such as Mount Sinai Health System and Toronto Western Hospital. Regulatory dialogues facilitated by STAIR have contributed to endpoints adopted in device approvals by FDA and conditional marketing authorizations considered by European Medicines Agency.

Controversies and Criticism

Critics from academic circles at University of Oxford and investigative commentators in outlets like The BMJ have alleged conflicts of interest due to industry participation from Pfizer, Eli Lilly, and Roche, echoing debates similar to those surrounding Physician Payments Sunshine Act disclosures and interactions scrutinized in reports by ProPublica. Some methodological critics affiliated with Cochrane Collaboration and Johns Hopkins University have argued that consensus statements lacked empirical validation and may have favored trial designs advantageous to certain sponsors, while policy analysts at Brookings Institution and ethicists from Kennedy Institute of Ethics have raised questions about transparency. STAIR has responded by publishing conflict of interest policies and inviting wider participation from groups such as Patient-Centered Outcomes Research Institute and international stroke networks.

Category:Medical organizations